Last $1.41 USD
Change Today -0.02 / -1.40%
Volume 73.3K
GENE On Other Exchanges
As of 2:13 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

genetic tech ltd-sp adr (GENE) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/20/13 - $3.35
52 Week Low
02/5/14 - $1.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENETIC TECH LTD-SP ADR (GENE)

genetic tech ltd-sp adr (GENE) Related Bloomberg News

View More Bloomberg News

genetic tech ltd-sp adr (GENE) Related Businessweek News

No Related Businessweek News Found

genetic tech ltd-sp adr (GENE) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and gene testing for gene related disorders. The company also provides DNA based tests comprising antenatal DNA testing, deceased estate DNA testing, DNA profiling, grandparent DNA testing, immigration DNA testing, legal paternity DNA testing, non-legal paternity DNA testing, sibling DNA testing, twins DNA testing, and Y-chromosome DNA testing services to determine parentage or relatedness. In addition, it offers animals’ tests consisting of disease testing, breed identification, coat color, and animal forensic DNA testing. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Founded in 1987

genetic tech ltd-sp adr (GENE) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$223.1K
Senior Vice President Sales & Marketing - Phe...
Total Annual Compensation: A$222.0K
Scientific Director
Total Annual Compensation: A$114.1K
Compensation as of Fiscal Year 2013.

genetic tech ltd-sp adr (GENE) Key Developments

Genetic Technologies Executes Settlement, Covenant and License Agreement with Promega Corporation

Genetic Technologies Limited reported the execution of a settlement, covenant and license agreement with Promega Corporation. Under this agreement, GTG grants broad rights to Promega in relation to GTG's Intron Sequence Analysis and Genomic Mapping patents. The precise commercial terms of this Agreement are covered by formal confidentiality provisions and cannot be disclosed.

Genetic Technologies Limited, Special/Extraordinary Shareholders Meeting, Apr 17, 2014

Genetic Technologies Limited, Special/Extraordinary Shareholders Meeting, Apr 17, 2014., at 10:00 AUS Eastern Standard Time. Location: 60-66 Hanover Street. Agenda: To approve the selective capital reduction by GTG and the disposal by GTG of shares in ImmunAid Limited ACN 096 281 542, to be effected by: the transfer to GTG by the Jacobson Entities of 75,937,500 ordinary shares in GTG (and their immediate cancellation); and (b) in exchange for the transfer by GTG to the Jacobson Entities of 4,500,000 shares in ImmunAid Limited.

Genetic Technologies Limited Announces Executive Changes

Genetic Technologies Limited announced that Ms. Alison Mew has confirmed that she will return to full-time work to resume her position the company's Chief Executive Officer as from 1 April 2014. In light of her return, Acting Chief Executive Officer Mr. Tom Howitt will relinquish this role on 28 March 2014. Further, the company advises that Mr. Howitt has tendered his resignation as Chief Financial Officer and company Secretary and will leave the company on that date. Until such time as a replacement for Mr. Howitt can be found, current GTG Financial Controller, Ms. Bronwyn Christie, will be appointed as Acting Chief Financial Officer and will also be appointed as Company Secretary.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENE:US $1.41 USD -0.02

GENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Sonic Healthcare Ltd A$17.67 AUD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation GENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECH LTD-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at